Older Adults Who Had COVID May Be More At Risk For Alzheimer's Disease
A new study on the virus shows just how much COVID might affect the brain. Here's what experts want you to know.Now, new research suggests that COVID may increase our risk of developing brain disorders like Alzheimer’s disease, too. The study, which was published this month in the Journal of Alzheimer’s Disease, found that older adults who were infected with COVID had a 50 to 80% higher chance of developing Alzheimer’s compared to people who’d never had COVID.
Promising data shows that an Alzheimer's drug can slow cognitive decline.
In a phase III clinical trial, with results published Tuesday in the New England Journal of Medicine, the drug, Lecanemab -- developed by Eisai and Biogen Inc. -- slowed the rate of cognitive decline by 27% in patients in the early stages of the disease, making it the first drug of its kind to produce such positive trial results, the study showed.
MORE: New Alzheimer's drug is 1st of its kind to be FDA approved
"Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in less decline than placebo on all measures of cognition and function at 18 months," said Dr. Christopher Van Dyck, director of the Yale Alzheimer's Disease Research Center, during his presentation of trial efficacy results at the Clinical Trials on Alzheimer's Disease meeting, held in San Francisco.
New Alzheimer's Drug Appears to Actually Work, to Some Degree
Last year, Biogen, a pharmaceutical company, released a drug called Aduhelm. It was the first new Alzheimer's drug approved by the FDA in almost 20 years, however its rollout was mired in controversy — vast swaths of experts decried its approval, claiming that there simply just wasn't enough evidence to support its efficacy, while the […]All that is to say that given last year's Aduhelm spectacle, you'd be forgiven for doubting what appears to be a promising development in Biogen's continued Alzheimer's drug development. And that's just what it announced with a collaborator, fellow pharmaceutical maker Eisai, on Tuesday.
Researchers followed nearly 1,800 patients over the course of 18 months and found the drug "resulted in moderately less decline on measures of cognition and function," compared to patients who received a placebo.
However, the companies noted that "longer trials are warranted to determine the efficacy and safety of Lecanemab in early Alzheimer's disease."
Patients who have Alzheimer's disease have build-up of two proteins, amyloid-beta and tau, in the brain. They clump together and form plaques, disrupting cell function and causing symptoms such as memory loss and confusion.
Lecanemab is a monoclonal antibody that helps remove the amyloid-beta clumps.
Mild cognitive impairment (MCI)
Learn more about this stage between the typical cognitive decline of aging and the more serious decline of dementia. MCI may include problems with memory, language or judgment. People with MCI may be aware that their memory or mental function has "slipped." Family and close friends also may notice changes. But these changes aren't bad enough to impact daily life or affect usual activities. MCI may increase the risk of dementia caused by Alzheimer's disease or other brain disorders. But some people with mild cognitive impairment might never get worse. And some eventually get better.
Trial participants were split into two groups, both with a Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score of about 3.2 when the trial began. This score, which measures dementia impairment, has a scale from 0 indicating no impairment to 18.0 indicating severe impairment. A score of 3.2 indicates very mild impairment.
Over the course of 18 months, patients in the Lecanemab group saw their score go up by 1.21 points in comparison with patients in the placebo group, who saw their score go up by 1.66 points.
MORE: Dementia, Alzheimer's not an inevitable part of aging: Study
There were some adverse events in the trial, the companies said, including about 20% of Lecanemab-treated patients who experienced brain swelling or brain bleeding, although side effects were largely asymptomatic.
Following the 18-month study, two patients died after experiencing brain hemorrhaging. However, Eisai said no deaths are considered linked to Lecanemab.
Alzheimer's experimental drug may slow progression of disease, but there are risks: experts
A study just published in the New England Journal of Medicine indicates that the experimental drug lecanemab showed a slowing of cognitive decline progression by 27% in those with early Alzheimer's."These findings show that lecanemab offers promise for people with early Alzheimer’s disease, with a significant slowing of decline and a reasonable safety profile," the study’s lead researcher, Dr. Christopher H. Van Dyck, told Fox News Digital in an interview.
Dr. Marwan Sabbah, a neurologist at the Barrow Neurological Institute, said during the presentation Tuesday that doctors will need to proceed with caution when thinking about whether or not to recommend the drug for patients on blood thinners.
The Alzheimer's Association said it was "encouraged" by the news and called on the U.S. Food and Drug Administration to give accelerated approval of Lecanemab. The FDA is currently slated to make an approval decision by Jan. 6, 2023.
If approved, the drug would likely only be given to patients who are in the very early stages of the disease, not to people who already have significant cognitive impairment.
"These peer-reviewed, published results show Lecanemab will provide patients more time to participate in daily life and live independently," the Alzheimer's Association said in a statement. "It could mean many months more of recognizing their spouse, children and grandchildren."
The statement continued, "Treatments that deliver tangible benefits to those living with mild cognitive impairment (MCI) due to Alzheimer's and early Alzheimer's dementia are as valuable as treatments that extend the lives of those with other terminal diseases."
4 New Breakthroughs in Alzheimer’s Research with Unprecedented Results, according to Doctors
With new treatments and new knowledge, we may be reaching a new era of hope for Alzheimer's disease. The post 4 New Breakthroughs in Alzheimer’s Research with Unprecedented Results, according to Doctors appeared first on The Healthy.
Researchers not involved in the study, including Dr. Leah Croll, a neurologist and assistant professor of neurology at the Lewis Katz School of Medicine at Temple University, said the results were promising.
"This is encouraging news for the millions of Americans affected by Alzheimer's disease, especially because the Alzheimer's drug pipeline has been met with many disappointments over the years," she told ABC News.
There have been hundreds of Alzheimer's drug trials over the years, most with disappointing results.
"Lecanemab is an important incremental change in the way we treat Alzheimer's," Croll said. "I'm hopeful that we are really starting to chip away at this disease process and that in the future, we will have even more options to offer patients."
If the drug gets FDA approval, cost could be a concern. For example, aducanumab, a controversial Alzheimer's drug that was approved last year despite critics arguing that trial data was conflicting, costs about $28,000 per year.